Monoclonal Antibodies +
Manage a flexible, scalable product portfolio.
Prepare for commercial success
Because you may not know which of your various molecules will be approved next, the ability to scale out production as soon as you get a green light is critical to your commercial success. With competitors at your heels, speed-to-market pressure has never been higher for your mAbs or therapeutic proteins product. You need a flexible manufacturing asset that can quickly pivot within an uncertain product pipeline and unknown timeline.
How can CRB help you?
To accelerate from clinical development to commercialization in a landscape of product variability, you need experts in your corner. Our teams draw on decades of experience delivering mammalian cell facilities and state-of-the-art biotech facilities to create a custom solution for you that ensures unit operation process flexibility, rapid capacity changes, and process efficiency. This gives you confidence in your development and manufacturing capabilities, no matter what enters your product pipeline next.
Whether you’re renovating an aging mAbs facility, developing a first-time in-house manufacturing line, or supporting the industry through an on-demand multimodal manufacturing space, CRB has the industry experience to get you there.
Therapeutic proteins and monoclonal antibodies are the lifeblood of the biotech industry. We’re here to facilitate your success and longevity within this market.
Tell us more about your project.
Download Now – Horizons: Life Sciences
Our 2022 edition of the life sciences report, built on the insights of nearly 500 industry leaders, explores the transformative change this field is poised to undergo in the wake of the pandemic and ever-increasing investment in R&D.